[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-333993-105":59,"doc-detail-333993-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","repurposing-of-c-met-inhibitor-tivantinib-inhibits-pediatric-neuroblastoma-cellular-growth","Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth","","Dysregulation of the receptor tyrosine kinase c-MET is linked to tumor development through oncogenic signaling, including in pediatric neuroblastoma (NB), a common extracranial solid cancer with poor long-term survival. Analysis of a large cohort showed high MET expression associates with worse overall survival, progression, relapse, and elevated MYCN levels. Repurposed tivantinib, a c-MET inhibitor, suppressed NB cellular growth, proliferation, and 3D spheroid formation across MYCN-amplified and non-amplified cell lines. It halted the cell cycle at G2/M, triggered apoptosis, and downregulated genes in PI3K, STAT, and Ras pathways, supporting c-MET targeting for high-risk NB.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-of-c-met-inhibitor-tivantinib-inhibits-pediatric-neuroblastoma-cellular-growth/333993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-of-c-met-inhibitor-tivantinib-inhibits-pediatric-neuroblastoma-cellular-growth/333993.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What relationship does the study find between MET expression and neuroblastoma outcomes?","Question",{"text":113,"@type":114},"High MET expression strongly correlates with poor overall survival, disease progression, relapse, and higher MYCN levels in neuroblastoma patients.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does tivantinib affect pediatric neuroblastoma cell growth?",{"text":118,"@type":114},"Tivantinib inhibits neuroblastoma cellular growth by blocking cell proliferation and suppressing 3D spheroid tumor formation and growth.",{"name":120,"@type":111,"acceptedAnswer":121},"What cellular mechanisms are altered by c-MET inhibition in the study?",{"text":122,"@type":114},"Tivantinib blocks the cell cycle at the G2/M phase transition, induces apoptosis, and inhibits expression of multiple genes in PI3K, STAT, and Ras signaling pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},333993,1790192975,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","pharmaceuticals  \nArticle  \nRepurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth  \nRameswari Chilamakuri  and Saurabh Agarwal *  \nCitation: Chilamakuri, R.; Agarwal, S. Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth. Pharmaceuticals 2024, 17, 1350 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ph17101350  \nAcademic Editor: Stephen J. Lewis  \nReceived: 28 August 2024  \nRevised: 22 September 2024  \nAccepted: 1 October 2024  \nPublished: 9 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, New York, NY 11439, USA  \n* Correspondence: [agarwals@stjohns.edu](agarwals@stjohns.edu); Tel.: +1-718-990-1623  \nAbstract: Background: Dysregulation of receptor tyrosine kinase c-MET is known to promote tumor development by stimulating oncogenic signaling pathways in different cancers, including pediatric neuroblastoma (NB) . NB is an extracranial solid pediatric cancer that accounts for almost 15% of all pediatric cancer-related deaths, with less than a 50% long-term survival rate. Results: In this study, we analyzed a large cohort of primary NB patient data and revealed that high MET expression strongly correlates with poor overall survival, disease progression, relapse, and high MYCN levels in NB patients. To determine the effects of c-MET in NB, we repurposed a small molecule inhibitor, tivantinib, and found that c-MET inhibition significantly inhibits NB cellular growth. Tivantinib significantly blocks NB cell proliferation and 3D spheroid tumor formation and growth in different MYCN-amplified and MYCN-non-amplified NB cell lines. Furthermore, tivantinib blocks the cell cycle at the G2/M phase transition and induces apoptosis in different NB cell lines. As expected, c-MET inhibition by tivantinib inhibits the expression of multiple genes in PI3K, STAT, and Ras cell signaling pathways. Conclusions: Overall, our data indicate that c-MET directly regulates NB growth and 3D spheroid growth, and c-MET inhibition by tivantinib maybe an effective therapeutic approach for high-risk NB. Further developing c-MET targeted therapeutic approaches and combining them with current therapies may pave the way for effectively translating novel therapies for NB and other c-MET-driven cancers.  \nKeywords: tivantinib; ARQ197; c-MET; neuroblastoma; drug repurposing  \n1. Introduction  \nCancer therapy has significantly advanced in recent decades, particularly in the treatment of solid tumors, yet substantial challenges remain. Conventional approaches, including surgery, chemotherapy, and radiation, have improved survival rates for many patients but often result in severe side effects and the development of resistance, especially in aggressive tumors like neuroblastoma (NB) . Emerging precise therapeutic approaches, including immunotherapy and gene editing, specifically target cancer cells and minimize side effects [1] . However, these therapies face notable limitations, such as immune evasion by tumors, genetic heterogeneity within solid tumors, and the high cost of personalized treatment strategies [1,2] . Addressing these challenges requires further research to enhance therapeutic efficacy, reduce toxicity, and improve access to advanced treatments.  \nNB is a common neuroendocrine solid tumor with highly diverse genetic, epigenetic, morphological, and biological characteristics, which complicates its diagnosis and treatment [3] . NB develops from neural crest cells of the peripheral nervous system and accounts for 6–10% of all ","cbCaitPC74CW653D","https://ap.wps.com/l/cbCaitPC74CW653D","pdf",2957125,15,"English","# Abstract\n# Introduction\n## Neuroblastoma background and challenges\n## Molecular features and targeted therapies\n## Role of receptor tyrosine kinases and c-MET signaling","[{\"question\":\"What relationship does the study find between MET expression and neuroblastoma outcomes?\",\"answer\":\"High MET expression strongly correlates with poor overall survival, disease progression, relapse, and higher MYCN levels in neuroblastoma patients.\"},{\"question\":\"How does tivantinib affect pediatric neuroblastoma cell growth?\",\"answer\":\"Tivantinib inhibits neuroblastoma cellular growth by blocking cell proliferation and suppressing 3D spheroid tumor formation and growth.\"},{\"question\":\"What cellular mechanisms are altered by c-MET inhibition in the study?\",\"answer\":\"Tivantinib blocks the cell cycle at the G2/M phase transition, induces apoptosis, and inhibits expression of multiple genes in PI3K, STAT, and Ras signaling pathways.\"}]","Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth | PDF",1790004909,38]